MOTS-c and Gabapentin Interaction: Safety, Pharmacology, and Clinical Guidance

MOTS-c (mitochondrial open reading frame of the 12S rRNA type-c) is an investigational 16-amino-acid mitochondrial-derived peptide studied for effects on insulin sensitivity and exercise metabolism. It is not FDA-approved and has no established prescribing label. Gabapentin (brand name Neurontin, generic available) is an FDA-approved anticonvulsant and neuropathic pain agent that has been on the market since 1993. No published pharmacokinetic or pharmacodynamic interaction study has directly tested these two compounds together as of this writing, and neither PubMed nor an FDA-guidance search returned a dedicated MOTS-c/gabapentin interaction study.

The direct answer

No pharmacokinetic interaction between MOTS-c and gabapentin has been demonstrated, because no study has tested the combination. What can be said with more confidence is that their elimination pathways are largely independent: gabapentin depends solely on renal filtration and is not metabolized by the liver, while MOTS-c is presumed to be degraded by circulating and tissue peptidases like other short peptides, a mechanism unrelated to cytochrome P450 enzymes or drug transporters. The evidence gap does not equal proof of safety. It means the assessment rests on mechanistic reasoning plus routine renal monitoring rather than trial data specific to this pair.

Why no formal interaction study exists

MOTS-c has not gone through the in vitro and in vivo drug-interaction testing that FDA guidance requires for new molecular entities seeking approval, because it is not an approved drug and has not completed that regulatory pathway (FDA guidance generally requires such in vitro and in vivo drug-interaction testing for new molecular entities seeking approval). Gabapentin, by contrast, has a decades-long, well-characterized pharmacokinetic profile documented in its FDA prescribing information (Neurontin label, accessdata.fda.gov).

That asymmetry, an approved drug with a mature label paired with an investigational peptide with no label at all, is the actual source of the "no known interaction" language seen elsewhere online. It reflects an absence of formal testing, not a tested-and-cleared result. Readers should not treat "no interaction reported" as equivalent to "studied and found safe."

What is established about gabapentin's pharmacokinetics

According to the FDA-approved label, gabapentin:

• Is absorbed via a saturable intestinal transport system, so bioavailability decreases as single doses increase.
• Is less than 3% protein-bound.
• Undergoes no hepatic metabolism; the entire absorbed dose is excreted unchanged in the urine.
• Has a half-life of roughly 5 to 7 hours in patients with normal renal function, which lengthens substantially as renal function declines.
• Requires dose reduction below an eGFR of 60 mL/min/1.73 m², with the label specifying step-down doses at lower eGFR thresholds.
• Interacts with aluminum/magnesium-containing antacids (reduced gabapentin absorption) and with morphine (increased gabapentin exposure), the two pharmacokinetic interactions the label specifically documents.

(Source: Neurontin prescribing information, FDA.)

Because gabapentin is not metabolized by the liver, it structurally cannot participate in a CYP-based interaction with any co-administered compound, peptide or otherwise.

What is plausible but unproven about MOTS-c

MOTS-c is a short peptide, and short peptides in general are degraded by plasma and tissue peptidases rather than by hepatic phase I/II enzymes. Extending that general peptide pharmacokinetic pattern to MOTS-c specifically is a reasonable inference, not a confirmed, MOTS-c-specific finding. Preclinical work has examined MOTS-c's role in AMPK activation and metabolic signaling, and small human studies have looked at exercise-induced changes in circulating MOTS-c. Those studies were designed to characterize MOTS-c's biology, not its interaction potential with anticonvulsants, and this draft does not carry forward specific effect sizes from that literature because the underlying citations could not be independently verified against the source material provided. Anyone relying on a precise number (percentage change in insulin sensitivity, fold-change in plasma levels, and similar figures sometimes quoted online) should ask for the primary paper before treating it as settled.

Where the two pathways actually meet: the kidney

Gabapentin clearance tracks creatinine clearance closely, which is why the FDA label builds dose reduction directly into eGFR bands rather than leaving it to clinical judgment. If MOTS-c degradation fragments are filtered renally, as would be expected for peptide breakdown products generally, they add some additional filtration load. In a patient with normal renal function, that added load is not expected to be clinically meaningful. In a patient with chronic kidney disease, gabapentin already requires dose adjustment regardless of any peptide use, and gabapentin accumulation in that setting is a recognized cause of confusion, myoclonus, and, in severe cases, more serious neurologic toxicity. That risk comes from gabapentin dosing relative to kidney function, not from a MOTS-c-specific interaction, but it means renal status is the variable worth tracking whenever the two are used together.

This is the compact takeaway: MOTS-c and gabapentin have not been studied together, but their known individual pharmacokinetics do not overlap at the CYP450, transporter, or protein-binding level; the only shared pathway is renal clearance, and that pathway only becomes clinically relevant when kidney function is already reduced, at which point gabapentin dosing needs adjustment under FDA labeling independent of MOTS-c use.

Evidence-status interaction assessment

Monitoring approach if both are being used

Baseline. Renal function (serum creatinine, calculated eGFR), current gabapentin dose and indication, and a full medication list including any glucose-lowering therapy.

Follow-up. Recheck renal function within 4 to 6 weeks of starting the combination, then on a routine interval consistent with the patient's overall renal risk. If the patient has diabetes or prediabetes, fasting glucose or HbA1c monitoring is reasonable given MOTS-c's studied association with insulin sensitivity, though this is a drug-disease consideration rather than a direct MOTS-c-gabapentin interaction.

Warning signs. New confusion, unusual sedation, or myoclonus should prompt reassessment of renal function and gabapentin dosing first, since these are recognized signs of gabapentin accumulation in reduced renal function. They should not be assumed to represent a MOTS-c effect without ruling out gabapentin dosing and kidney function as the more established explanation.

When to seek urgent care. Marked confusion, difficulty breathing, or loss of coordination in someone taking gabapentin, especially with any degree of kidney impairment, warrants prompt medical evaluation rather than waiting for a scheduled follow-up.

What this article cannot tell you

This is a mechanism-based assessment, not a substitute for an interaction study that has not been done. It cannot tell you the individualized dose of either compound that is appropriate for a specific patient, and dosing decisions should be made by a treating clinician who knows the patient's renal function, full medication list, and the reason MOTS-c is being considered. Because MOTS-c is not FDA-regulated, product quality and labeled content can vary by supplier, which is a separate safety issue from the pharmacology discussed here.

Evidence boundary

Established: Gabapentin's pharmacokinetics (no hepatic metabolism, low protein binding, renal-dependent dosing) are documented in its FDA label. Short peptides in general are cleared by peptidase degradation rather than hepatic or CYP-based metabolism.

Plausible but unproven: That MOTS-c specifically follows the same peptidase-degradation pattern documented for peptides generally; that MOTS-c's metabolic effects could meaningfully add to hypoglycemia risk in a patient on gabapentin plus other diabetes medications.

Not established: Any direct pharmacokinetic or pharmacodynamic interaction between MOTS-c and gabapentin, because no dedicated study of the combination has been published.